Laresin (Olmesartan Medoxomil)

Olmesartan medoxomil selectively blocks AT1 receptors, which are the primary binding sites for angiotensin II. This inhibition prevents angiotensin‑II‑induced vasoconstriction and aldosterone release, leading to relaxed blood vessels, decreased sodium and water retention, and a subsequent reduction in arterial blood pressure.

The appropriate dose of Laresin is determined by the prescribing clinician based on the patient’s blood‑pressure readings, overall health status, and response to therapy. Dosage adjustments are made during follow‑up visits to achieve optimal blood‑pressure control while minimizing adverse effects.

The safety of olmesartan medoxomil during pregnancy has not been established, and it is generally contraindicated once pregnancy is confirmed because of potential fetal toxicity. Limited data are available for breastfeeding; therefore, the benefits and risks should be carefully evaluated by a healthcare professional before use.

To place an order, submit an enquiry on the Laresin product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Laresin belongs to the ARB class, offering blood‑pressure reduction comparable to ACE inhibitors but with a lower incidence of cough and angioedema. Compared with calcium‑channel blockers, ARBs primarily affect the renin‑angiotensin system rather than vascular smooth‑muscle calcium influx, providing an alternative mechanism for patients who do not tolerate other classes.

Laresin tablets should be stored at ambient temperature, preferably below 25 °C, in a dry place away from direct sunlight. Keep the medication in its original container to protect it from moisture and accidental ingestion by children.

Laresin is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider and not alter the dose without medical advice.

Serious risks include hyperkalemia, especially when combined with potassium‑sparing agents, acute kidney injury, and rare cases of angioedema. Patients should be monitored for signs of swelling, difficulty breathing, or sudden changes in kidney function and electrolyte levels.

Laresin is contraindicated in patients with known hypersensitivity to olmesartan medoxomil or any component of the formulation. It should also be avoided in individuals with severe hepatic impairment, and it is not recommended for use during pregnancy once gestation is confirmed.